Search

Displaying results 2691 - 2700 of 4690 in total
  1. Drug

    Dactylis glomerata pollen

    go.drugbank.com/drugs/DB10379
    Approved

    Dactylis glomerata pollen is the pollen of the Dactylis glomerata plant. Dactylis glomerata pollen is mainly used in allergenic testing.

    Mixtures: K-O-T Standardized Grass Pollen Mix, K-O-T Standardized Grass Pollen Mix
  2. Drug

    Lolium perenne pollen

    go.drugbank.com/drugs/DB10389
    Approved

    Lolium perenne pollen is the pollen of the Lolium perenne plant. Lolium perenne pollen is mainly used in allergenic testing.

  3. Drug

    Methantheline

    go.drugbank.com/drugs/DB00940
    Approved

    Methantheline is a synthetic antispasmodic. Antispasmodics are used to relieve cramps or spasms of the stomach, intestines, and bladder. Methantheline is used to treat intestine or stomach ulcers (peptic ulcer disease), intestine problem...

  4. Drug

    Butalbital

    go.drugbank.com/drugs/DB00241
    ApprovedIllicit

    Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group.

  5. Drug

    Anthoxanthum odoratum

    go.drugbank.com/drugs/DB14163
    Approved

    Anthoxanthum odoratum allergenic extract is used in allergenic testing.

  6. Drug

    CX-051869

    go.drugbank.com/drugs/DB31656
    Approved

    CX-051869 is a COVID-19 mRNA vaccine encoding the pre-fusion stabilized Spike glycoprotein (S) of the SARS-CoV-2 Omicron variant lineage LP.8.1. It is the active ingredient of the 2025-2026 formulation of Moderna's Spikevax vaccine.

  7. Drug

    Dulaglutide

    go.drugbank.com/drugs/DB09045
    ApprovedInvestigational

    Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct … [A236070] Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular

  8. Drug

    Antihemophilic factor (recombinant), PEGylated

    go.drugbank.com/drugs/DB09329
    ApprovedInvestigational

    Antihemophilic Factor (Recombinant), PEGylated, was approved by the FDA in December 2016 as the product _Adynovate_ [FDA label].

  9. Drug

    Cretostimogene grenadenorepvec

    go.drugbank.com/drugs/DB05148
    Investigational

    CG0070 can potentially destroy cancer cells by two different mechanisms: direct cell killing by the virus and immune-mediated cell killing stimulated by GM-CSF.

  10. Drug

    Ambroxol

    go.drugbank.com/drugs/DB06742
    ApprovedInvestigational

    It stimulates synthesis and release of surfactant by type II pneumocytes. … Surfactants acts as an anti-glue factor by reducing the adhesion of mucus to the bronchial wall, in improving its transport and in providing protection against infection and irritating agents.

    Products: K-NOUL, AMBROXOL MK 30MG TABLETAS